Tegafur-uracil as a Maintenance Therapy for Non-metastatic Nasopharyngeal Carcinoma: Insights from the Literature
Anticancer Research · 2025
DOI: 10.21873/anticanres.17726 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Anticancer Research, 2025. Verfasst von Tung-Lung Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, …. Hauptthemen laut MEDLINE: Tegafur, Uracil, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Nasopharyngeal carcinoma (NPC) remains a challenging malignancy with high rates of recurrence following definitive therapy. This meta-analysis aimed to evaluate the efficacy of tegafur-uracil (UFT) maintenance therapy in patients with non-metastatic NPC after curative treatment. A systematic literature search of PubMed, Embase, and the Cochrane Library was performed to identify eligible studies. Three retrospective cohort studies including a total of 558 patients were analyzed. Random-effects meta-analysis demonstrated that UFT maintenance therapy significantly improved both progression-free survival [hazard ratio (HR)=0.53, 95% confidence interval (CI)=0.35-0.81] and overall survival (HR=0.37, 95%CI=0.21-0.65) compared to observation alone. Sensitivity analyses confirmed the robustness of these findings. However, trial sequential analysis indicated that the cumulative evidence did not meet the a priori information size required for a conclusive result, highlighting the need for further high-quality studies. In summary, UFT maintenance therapy may represent a promising option to reduce recurrence and improve survival in non-metastatic NPC, particularly in settings where access to novel agents is limited, but additional prospective studies are needed to confirm its clinical benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.
- Department of Oncology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.
- Division of Hematology and Oncology, Department of Internal Medicine, Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
- Neurological Institute, Changhua Christian Hospital, Changhua, Taiwan, R.O.C.
- Department of Otolaryngology-Head and Neck Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.
- Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, R.O.C.; ndmc_tw.tw@yahoo.com.tw.
Zitieren
APA
Yang, T. L., Chen, P. H., Lee, H. L., Jhou, H. J., Lee, C. H., Lee, J. C., Chu, Y. H., & Chen, J. H. (2025). Tegafur-uracil as a Maintenance Therapy for Non-metastatic Nasopharyngeal Carcinoma: Insights from the Literature. Anticancer Research. https://doi.org/10.21873/anticanres.17726
Vancouver
Yang TL, Chen PH, Lee HL, Jhou HJ, Lee CH, Lee JC, et al. Tegafur-uracil as a Maintenance Therapy for Non-metastatic Nasopharyngeal Carcinoma: Insights from the Literature. Anticancer Research. 2025. doi:10.21873/anticanres.17726
BibTeX
@article{Yang2025,
author = {Yang, Tung-Lung and Chen, Po-Huang and Lee, Hsu-Lin and Jhou, Hong-Jie and Lee, Cho-Hao and Lee, Jih-Chin and Chu, Yueng-Hsiang and Chen, Jia-Hong},
title = {Tegafur-uracil as a Maintenance Therapy for Non-metastatic Nasopharyngeal Carcinoma: Insights from the Literature},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17726}
}
EUVIMED